---
title: "Nomura Adjusts Akeso's Price Target to HK$112.73 From HK$120.64, Keeps at Neutral"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/277909219.md"
description: "Nomura Adjusts Akeso's Price Target to HK$112.73 From HK$120.64, Keeps at Neutral"
datetime: "2026-03-05T09:10:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277909219.md)
  - [en](https://longbridge.com/en/news/277909219.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277909219.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/277909219.md) | [繁體中文](https://longbridge.com/zh-HK/news/277909219.md)


# Nomura Adjusts Akeso's Price Target to HK$112.73 From HK$120.64, Keeps at Neutral



### 相关股票

- [AKESO (09926.HK)](https://longbridge.com/zh-CN/quote/09926.HK.md)

## 相关资讯与研究

- [Akeso's Ivonescimab Shows Strong Phase 3 Results in Lung Cancer Trial](https://longbridge.com/zh-CN/news/261967652.md)
- [The Bull Case For Akeso (SEHK:9926) Could Change Following FDA Clearance Of Global Gastric Cancer Trial](https://longbridge.com/zh-CN/news/269971630.md)
- [Macquarie Downgrades Prada to Neutral from Outperform, Price Target is HK$46](https://longbridge.com/zh-CN/news/278094455.md)
- [Akeso’s Ivonescimab Shows Promising Results in HARMONi-6 Trial for Advanced sq-NSCLC](https://longbridge.com/zh-CN/news/261782987.md)
- [Akeso Reports Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer Study](https://longbridge.com/zh-CN/news/272494568.md)